Immune suppression and considerations for dental care

Dental Clinics of North America

Volumn 47, Issue 4, 2003, Pages 709-731

  Parisi, Ernesta ^a   Glick, Michael ^b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN; FLUCONAZOLE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; MACROLIDE; NAFCILLIN; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CLINICAL FEATURE; DENTAL CARE; DISEASE PREDISPOSITION; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEALTH CARE; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASIA; NEUTROPENIA; PATHOGENESIS; PRIMARY IMMUNE RESPONSE; PROPHYLAXIS; REVIEW; RISK FACTOR;

DENTAL CARE FOR CHRONICALLY ILL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; TRANSPLANTATION IMMUNOLOGY;

EID: 3242763806     PISSN: 00118532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-8532(03)00038-7     Document Type: Review

References (80)

1. Paul W.E. The immune system: an introduction. Paul W.E. Fundamental immunology. 4th edition:1999;Lippincott-Raven, Philadelphia
2. Bennett J.C. Approach to the patient with immune disease. Goldman L., Bennett J.C. Cecil textbook of medicine. 21st edition:2000;1423-1429 W.B: Saunders, Philadelphia
3. Schindler L.W. The immune system - how it works. 1996;NIAID and NCI, Bethesda (MD). NIH Publication No. 96-3229; p. 1-25
4. Pizzo P.A. The compromised host. Goldman L., Bennett J.C. Cecil textbook of medicine. 21st edition:2000;1569-1581 W.B: Saunders, Philadelphia
5. Sepkowitz K.A. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 34:2002;1098-1107
6. Office of Communications and Public Liaison. Bethesda (MD): NIAID, NIH. Fact sheet: primary immune deficiency. August 2002. Available at: http://www.niaid.nih.gov/factsheets/pid.htm.
7. Ten R.M. Primary immunodeficiencies. Mayo Clin Proc. 73:1998;865-872
8. National Institute of Child Health and Human Development, NIH. When the body's defenses are missing. Primary immunodeficiency. Bethesda (MD): NIH Pub. No 99-4149, June 1999. p. 18. Available at: http://www.nichd.nih.gov/ publications/pubs/primaryimmunobooklets.htm.
9. Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol. 109:2002;581-591
10. Buckley R.H. Primary immunodeficiency diseases. Goldman L., Bennett J.C. Cecil textbook of medicine. 21st edition:2000;1433-1440 W.B. Saunders, Philadelphia
11. Carugati A., Pappalardo. Zingale L.C., Cicardi M. C1-inhibitor deficiency and angioedema. Mol Immunol. 38:2001;161-173
12. Puck J.M. Primary immunodeficiency diseases. JAMA. 278:1997;1835-1841
13. National Institute of Child Health and Human Development, NIH. When the body's defenses are missing. Primary immunodeficiency. Bethesda (MD): NIH Pub. No 99-4149, June 1999. p. 2. Available at: http://www.nichd.nih.gov/ publications/pubs/primaryimmunobooklets.htm.
14. DePauw B.E., Donnelley J.P. Infections in the immunocompromised host: general principles. Mandell G.L., Bennett J.E., Dolin R. Principles and practices of infectious diseases. 5th edition:2000;3079-3084 Churchill Livingstone, Philadelphia
15. Boxer L.A. Approach to the patient with leukopenia. Humes H.D. Kelley's textbook of internal medicine. 4th edition:2000;Lippincott Williams & Wilkins, Philadelphia
16. Bodey G.P., Buckley M., Sathe Y.S., Freireich E.J. Quantitative relationships between circulatory leukocytes and infection in patients with acute leukemia. Ann Intern Med. 61:1966;328
17. Stroncek D. Neutrophil alloantigens. Transfus Med Rev. 16:2002;67-75
18. Lekstrom-Himes J.A., Gallin J.I. Advances in immunology: immunodeficiency disease caused by defects in phagocytes. N Engl J Med. 343:2000;1703-1714
19. Bernini J.C. Diagnosis and management of chronic neutropenia during childhood. Pediatr Clin North Am. 43:1996;773-792
20. Palmer S.E., Stephens K.B., Dale D.C. Genetics, phenotype, and natural history of autosomal dominant cyclic hematopoeisis. Am J Med Genet. 66:1996;413-422
21. Manoucher-Pour M., Spagnuolo P.J., Rodman H.M., et al. Comparison of neutrophil chemotactic response in diabetic patients with mild and severe periodontal disease. J Periodontol. 52:1981;410-415
22. Diabetes Control and Complications Trial Research Group. Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:1993;977-986
23. Matloubian M., Suresh M., Glass A., Galvan M., Chow K., Whitmire J.K., et al. A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol. 73:1999;2527-2536
24. Patton L.L. Sensitivity, specificity, and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 90:2000;182-188
25. Swaminathan S., Nandini K.S., Hanna L.E., Somu N., Narayanan P.R., Barnes P.F. T-lymphocyte subpopulations in tuberculosis. Indian Pediatr. 37:2000;489-495
26. Salazar J.C., Hazlett K.R., Radolf J.F. The immune response to infection with treponema pallidum, the stealth pathogen. Microbes Infect. 4:2002;1133-1140
27. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 29:2001;1303-1310
28. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 101:1992;1644-1655
29. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med. 348:2003;138-150
30. Neurman J.H., Pyrhonen S., Teerenhovi L., et al. Oral sources of septicaemia in patients with malignancies. Oral Oncol. 33:1997;389
31. Oberholzer A., Oberholzer C., Moldawer L.L. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock. 16:2001;83-96
32. US Cancer Statistics Working Group. United States Cancer Statistics: 1999 incidence. 2002;Dept. of Health & Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta, Georgia
33. Navari R.M., Buckner C.D., Clift R.A., et al. Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants. Am J Med. 76:1984;564-572
34. Driezen S., McCredie K.B., Keating M.J., Bodey G.P. Oral infections associated with chemotherapy in adults with acute leukemia. Postgrad Med. 71:1982;133-146
35. Driezen S., Bodey G.P., Valdivieso M. Chemotherapy-associated oral infections in adults with solid tumors. Oral Surg. 55:1983;113-120
36. Peterson D.E. Pretreatment strategies for infection prevention in chemotherapy patients. NCI Monogr. (9):1990;61-71
37. Peterson D.E. Oral infections in the immunocompromised host. International Association for Dental Research symposium 19 April 1991, Acapulco, Mexico. J Oral Pathol Med. 21:1992;193-198
38. NIH Consensus Development Conference Summary. Oral complications of cancer therapies: diagnosis, prevention and treatment. JADA. 119:1989;179-183
39. CDCP. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR. 49:(No.RR-10):2000;14-50
40. Heaney M.L., Golde D.W. Myelodyspasia. N Engl J Med. 340:1999;1649-1660
41. Paradisi F., Corti G., Cinelli R. Infections in multiple myeloma. Infect Dis Clin North Am. 15:2001;373-384
42. Egerer G., Hensel M., Ho A.D. Infectious complications in chronic lymphoid malignancy. Curr Treat Options Oncol. 2:2001;237-244
43. Tsiodras S., Samonis G., Keating M.T., Kontoyiannis D.P. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc. 75:2000;1039-1054
44. 2001 OPTN/SRTR Annual Report 1991-2000. HHS/HRSA/OSP/DOT; UNOS; URREA. Available at: http://www.ustransplant.org/annual.html.
45. Simon D.M., Levin S. Infectious complications of solid organ transplantations. Infect Dis Clin North Am. 15:2001;521-549
46. Peterson D.E., Minah G.E., Overholser C.D., et al. Microbiology of acute periodontal infection in myelosupressed cancer patients. J Clin Oncol. 5:1997;1461
47. Fishman J.A., Rubin R.H. Infection in organ transplant recipients. N Engl J Med. 338:1998;1741
48. Patel R. Infections in recipients of kidney transplants. Infec Dis Clin North Am. 15:2001;901-952
49. Cohen D., Galbraith C. General health management and long-term care of the renal transplant recipient. Am J Kidney Dis. 38:2001;S10-S24
50. Antin J.H. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med. 347:2002;36-42
51. Storek J., Dawson M.A., Storer B., et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood. 97:2001;3380-3389
52. van Vurik J.H., Weisdorf D.J. Infections in recipients of blood and marrow transplantation. Hematol Oncol Clin North Am. 13:1999;1065-1089
53. Freifeld A.G., Walsh T.J., Pizzo P.A. Infections in the cancer patient. DeVita V.T. Jr., Hellman S., Rosenberg S.A. Cancer: principles and practice of oncology. 5th edition:1997;Lippincott-Raven, Philadelphia
54. Ochs L., Shu X.O., Miller J., et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood. 86:1995;3979-3986
55. Bush W.W. Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression. Adv Pract Acute Crit Care. 10:1999;253-269
56. Thomas D.W., Baboolal K., Subramanian N., Newcombe R.G. Cyclosporin A-induced gingival overgrowth is unrelated to allograft function in renal transplant recipients. J Clin Periodontol. 28:2001;706-709
57. Desai P., Silver J.G. Drug-induced gingival enlargements. J Can Dent Assoc. 64:1998;263-268
58. Seymour R.A., Thomason J.M., Ellis J.S. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol. 23:1996;165-175
59. Tunkel A.R., Sepkowitz K.A. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 34:2002;1524-1529
60. US Department of Health and Human Services. Oral health in America: a report of the surgeon general. 2000;US Department of Health and Human Services, NIDCR, NIH, Rockville, MD
61. DePaola J.G., Mangan D., Mills S.E., Costerton W., Barbeau J., Shearer B., et al. A review of the science regarding dental unit waterlines. J Am Dent Assoc. 133:2002;1199-1206
62. Department of Health and Human Services. Centers for Disease Control and Prevention. Draft recommended infection control practices for dentistry, 2003. Available at: http://www.cdc.gov/OralHealth/infection_control/guidelines/ comments.htm.
63. Mills S.E. The dental unit waterline controversy: defusing the myths, defining the solutions. J Am Dent Assoc. 131:2000;1427-1441
64. Reinthaler F.F., Mascher F., Stunzner D. Serological examinations for antibodies against legionella species in dental personnel. J Dent Res. 67:1988;942-943
65. Laurence R.A., Lapierre S.T. Quality of hemodialysis water: a 7-year multicenter study. Am J Kidney Dis. 25:1995;738-750
66. Emmerson A.M. Emerging waterborne infections in health-care settings. Emerg Infect Dis. 7:2001;272-276
67. Sixou J.L., Medeiros-Batista O.M., Bonnaure-Mallet M. Modifications of the microflora of the oral cavity arising during immunosuppressive chemotherapy. Eur J Cancer. Part B, Oral Oncol. 32B:1996;306-310
68. Bochud P.-Y., Calandra T., Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med. 97:1994;256-264
69. Fourrier F., Duvivier B., Boutigny H., Roussel-Delvallez M., Copin C. Colonization of dental plaque: a source of nosocomial infections in intensive care unit patients. Crit Care Med. 26:1998;301-308
70. Heimdahl A., Gahrton G., Groth C.-C., et al. Selective decontamination of the alimentary tract microbial flora in patients treated with bone marrow transplantation. Scand J Infect Dis. 16:1984;51-60
71. Epstein J.B., Chow A.W. Oral complications associated with immunosuppression and cancer therapies. Infect Dis Clin North Am. 19:1999;901-923
72. Ferretti G.A., Brown A.T., Raybould T.P., Lillich T.T. Oral antimicrobial agents - chlorhexidine. NCI Monogr. (9):1990;51-55
73. Bender I.B., Barkan M.J. Dental bacteremia and its relationship to bacterial endocarditis: preventive measures. Compendium. 10:1989;472-482
74. Scully C. Oral infections in the immunocompromised patient. Br Dent J. 172:1992;401-407
75. Garfunkel A.A., Glick M. Common oral findings in two different diseases - leukemia and AIDS: part 2. Compendium. 13:1992;550-556
76. Meyer U., Kleinheinz J., Handschel J., Kruse-Loser B., Weingart D., Joos U. Oral findings in three different groups of immunocompromised patients. J Oral Pathol Med. 29:2000;153-158
77. Holmstrup P., Glick M. Treatment of periodontal disease in the immunodeficient patient. Periodontol 2000. 28:2002;190-205
78. Ariyawardana S., Hay K.D. Oral manifestations and dental management of immunocompromised patients. N Z Dent J. 95:1999;89-97
79. Glick M. Glucocorticosteroid replacement therapy: a literature review and suggested replacement therapy. Oral Surg Oral Med Oral Pathol. 67:1987;614-620
80. Epstein J.B., Chow A.W. Oral complications associated with immunosuppression and cancer therapies. Infect Dis Clin North Am. 19:1999;901-923